The results of this study provide positive proof of concept for PARP inhibition in BRCA-deficient breast cancers and show a favorable therapeutic index for a novel targeted treatment strategy in patients with tumors that have genetic loss of function of BRCA1-associated or BRCA2-associated DNA repair.15 The gene discussed is BRCA2; the disease is breast cancer.